Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials | Synapse

April 25, 2019Open Access

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment-related adverse events in clinical trials provides an important guide for clinicians.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Wang et al. (Thu,) studied this question.

synapsesocial.com/papers/69d74dbdb54ccf0cfef30ce3 https://doi.org/https://doi.org/10.1001/jamaoncol.2019.0393

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Statistics in Medicine2006 · 1,246 citations
2Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer2018 · 120 citations
3Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial2017 · 295 citations
4Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer2018 · 1,815 citations
5Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 1432017 · 491 citations